Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan PharmaFRA:IP40 +4.51%62 Earnings per Share (Diluted) is €-0.33 as of Mar. 2026. GuruFocus rates FRA:IP40 with a GF Score™ of 62/100 and a GF Value™ of €9.51 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,521 Consumer Packaged Goods companies, InnoCan Pharma ranks better than 74.95% on this metric.
InnoCan Pharma's EPS (Basic) for the
three
months ended in Mar. 2026 was €-0.19.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.33.
During the past 3 years, the average EPS without NRIGrowth Rate was 30.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 21.30% per year.
During the past 8 years, InnoCan Pharma's highest 3-Year average EPS without NRI Growth Rate was 30.00% per year. The lowest was -64.10% per year. And the median was 9.90% per year.
InnoCan Pharma (FRA:IP40) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
InnoCan Pharma Earnings per Share (Diluted) Related Terms
InnoCan Pharma Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IP40 vs PG, CL, KVUE: Earnings per Share (Diluted) Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma PE Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's PE Ratio distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's PE Ratio falls into.
InnoCan Pharma Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
InnoCan Pharma's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €-0.33 mean?
InnoCan Pharma (FRA:IP40) has a Earnings per Share (Diluted) of €-0.33 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #381 out of 1521 companies in the Consumer Packaged Goods industry, placing it in the top 25%.
Is InnoCan Pharma's Earnings per Share (Diluted) too high?
InnoCan Pharma's current Earnings per Share (Diluted) is €-0.33. Based on the distribution chart, InnoCan Pharma ranks #381 out of 1521 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, InnoCan Pharma has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Earnings per Share (Diluted) compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #381 out of 1521 companies for Earnings per Share (Diluted). This places InnoCan Pharma in the top 25% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Consumer Packaged Goods company?
The median Earnings per Share (Diluted) among Consumer Packaged Goods companies is 7.30, based on 1,521 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Earnings per Share (Diluted) is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Earnings per Share (Diluted) is €-0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.51, compared to a current price of €1.51 — trading 84.2% below its estimated fair value. The current Earnings per Share (Diluted) is €-0.33. InnoCan Pharma's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Earnings per Share (Diluted) is €-0.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.51 is trading 84.2% below its estimated GF Value™ of €9.51.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for FRA:IP40:
Earnings per Share (Diluted): €-0.33
GF Value™: €9.51 vs. price of €1.51 (84.2% below fair value)
No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
62GF Score
Get the complete analysis for FRA:IP40
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IP40 has been successfully added to your 
